{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:49:04Z","timestamp":1788414544023,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cld.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T02:10:47Z","timestamp":1622167847000},"page":"603-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Emerging Therapies for Alcoholic Hepatitis"],"prefix":"10.1016","volume":"25","author":[{"given":"Ma Ai","family":"Thanda Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pyrsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s10620-019-5471-7","article-title":"Charges for alcoholic cirrhosis exceed all other etiologies of cirrhosis combined: a national and state inpatient survey analysis","volume":"64","author":"Barritt","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG clinical guideline: alcoholic liver disease","volume":"113","author":"Singal","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1016\/j.cld.2021.03.006_bib4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","article-title":"Alcoholic hepatitis","volume":"360","author":"Lucey","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.gtc.2011.06.008","article-title":"Alcoholic hepatitis: prognostic models and treatment","volume":"40","author":"Singal","year":"2011","journal-title":"Gastroenterol Clin North Am"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","article-title":"Alcoholic hepatitis: current challenges and future directions","volume":"12","author":"Singal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2021.03.006_bib7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/acer.13108","article-title":"Diagnosis and treatment of alcoholic hepatitis: a systematic review","volume":"40","author":"Singal","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis","volume":"41","author":"Dunn","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.cld.2021.03.006_bib11","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 Days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.cld.2021.03.006_bib13","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cld.2021.03.006_bib14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/lt.24208","article-title":"Liver transplantation for alcoholic hepatitis: a survey of liver transplant centers","volume":"21","author":"Hasanin","year":"2015","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190823","article-title":"Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis","volume":"13","author":"Marot","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cld.2021.03.006_bib16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.25544","article-title":"Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database","volume":"55","author":"Singal","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2018.10.026","article-title":"Current trials and novel therapeutic targets for alcoholic hepatitis","volume":"70","author":"Singal","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174544","article-title":"Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice","volume":"12","author":"Lowe","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2008.10.028","article-title":"Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats","volume":"50","author":"Keshavarzian","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib22","first-page":"79","article-title":"Gut\u207bliver axis: how do gut bacteria influence the liver?","volume":"6","author":"Konturek","year":"2018","journal-title":"Med Sci (Basel)"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3350\/cmh.2017.0067","article-title":"Microbiota, a key player in alcoholic liver disease","volume":"24","author":"Cassard","year":"2018","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2018.10.019","article-title":"Microbiome as a therapeutic target in alcohol-related liver disease","volume":"70","author":"Sarin","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00109-016-1474-4","article-title":"Interaction between gut microbiota and toll-like receptor: from immunity to metabolism","volume":"95","author":"Yiu","year":"2017","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/nure.12089","article-title":"Clinical applications of bovine colostrum therapy: a systematic review","volume":"72","author":"Rathe","year":"2014","journal-title":"Nutr Rev"},{"issue":"Supplement 2","key":"10.1016\/j.cld.2021.03.006_bib27","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jceh.2015.07.037","article-title":"Corticosteroids and bovine colostrum in treatment of alcoholic hepatitis \u2018in Extremis\u2019: a pilot study","volume":"5","author":"Sidhu","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2021.03.006_bib28","unstructured":"Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01968382. Assessed January 27, 2020."},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0884533611433534","article-title":"Zinc and liver disease","volume":"27","author":"Mohammad","year":"2012","journal-title":"Nutr Clin Pract"},{"issue":"10","key":"10.1016\/j.cld.2021.03.006_bib30","doi-asserted-by":"crossref","first-page":"e76522","DOI":"10.1371\/journal.pone.0076522","article-title":"Dietary zinc deficiency exaggerates ethanol-induced liver injury in mice: involvement of intrahepatic and extrahepatic factors","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.cld.2021.03.006_bib31","doi-asserted-by":"crossref","first-page":"G757","DOI":"10.1152\/ajpgi.00442.2014","article-title":"Zinc deficiency mediates alcohol-induced apoptotic cell death in the liver of rats through activating ER and mitochondrial cell death pathways","volume":"308","author":"Sun","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib32","doi-asserted-by":"crossref","first-page":"1444A","DOI":"10.1002\/hep.30353","article-title":"IL-1 receptor antagonist in combination with pentoxifylline and zinc for severe alcoholic hepatitis: a multicenter randomized double- bind placebo-controlled clinical trial","volume":"68","author":"Szabo","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib33","doi-asserted-by":"crossref","first-page":"e53028","DOI":"10.1371\/journal.pone.0053028","article-title":"Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment","volume":"8","author":"Bull-Otterson","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cld.2021.03.006_bib34","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","article-title":"In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA","volume":"152","author":"Vergis","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2021.03.006_bib35","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2017.02.030","article-title":"Infection in severe alcoholic hepatitis: yet another piece in the puzzle","volume":"152","author":"Singal","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2021.03.006_bib37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-2036.2009.03958.x","article-title":"Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis","volume":"29","author":"Vlachogiannakos","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2021.03.006_bib38","doi-asserted-by":"crossref","first-page":"S816","DOI":"10.1016\/S0168-8278(18)31905-6","article-title":"Use of rifaximin in alcoholic hepatitis: pilot study","volume":"69","author":"Jimenez","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.alcohol.2008.12.009","article-title":"Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis","volume":"43","author":"Forsyth","year":"2009","journal-title":"Alcohol."},{"key":"10.1016\/j.cld.2021.03.006_bib40","doi-asserted-by":"crossref","first-page":"9097276","DOI":"10.1155\/2019\/9097276","article-title":"Probiotics for alleviating alcoholic liver injury","volume":"2019","author":"Gu","year":"2019","journal-title":"Gastroenterol Res Pract"},{"issue":"11","key":"10.1016\/j.cld.2021.03.006_bib41","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/MEG.0000000000000458","article-title":"Effects of probiotics (cultured Lactobacillus subtilis\/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study","volume":"27","author":"Han","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis","volume":"37","author":"Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.cld.2021.03.006_bib44","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0168-8278(20)30865-5","article-title":"Role of fecal microbiota transplantation in severe alcoholic hepatitis: assessment of impact on prognosis and short-term outcomes","volume":"73","author":"Dhiman","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/(SICI)1096-9896(199809)186:1<82::AID-PATH151>3.0.CO;2-D","article-title":"Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis","volume":"186","author":"Afford","year":"1998","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(00)80219-6","article-title":"Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids","volume":"32","author":"Ta\u00efeb","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.03.006_bib47","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/hep.26169","article-title":"Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury, steatohepatitis, and steatosis","volume":"57","author":"Barnes","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.03.006_bib48","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/j.gastro.2004.01.022","article-title":"Activated natural killer T\u00a0cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption","volume":"126","author":"Minagawa","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1530-0277.2008.00842.x","article-title":"A\u00a0recent perspective on alcohol, immunity, and host defense","volume":"33","author":"Szabo","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cld.2021.03.006_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: mechanisms of injury and targeted treatment","volume":"12","author":"Louvet","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2021.03.006_bib51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/liv.13430","article-title":"Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice","volume":"37","author":"Iracheta-Vellve","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2021.03.006_bib52","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.cld.2021.03.006_bib53","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17512433.2016.1204910","article-title":"Canakinumab for the treatment of active systemic juvenile idiopathic arthritis","volume":"9","author":"Orrock","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/1744666X.2019.1707664","article-title":"Canakinumab for the treatment of adult-onset Still's disease","volume":"16","author":"Sfriso","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2018.05.012","article-title":"Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis","volume":"69","author":"Peeraphatdit","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib56","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib57","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2021.03.006_bib58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9972","key":"10.1016\/j.cld.2021.03.006_bib59","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2021.03.006_bib61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep4.1360","article-title":"Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism","volume":"3","author":"Gracia-Sancho","year":"2019","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.21561","article-title":"Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis","volume":"45","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib64","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib65","doi-asserted-by":"crossref","first-page":"e123294","DOI":"10.1172\/jci.insight.123294","article-title":"ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model","volume":"5","author":"Schuster-Gaul","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.cld.2021.03.006_bib66","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cld.2021.03.006_bib68","first-page":"8A","article-title":"Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial","volume":"68","author":"Mathurin","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib69","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1152\/ajpendo.00552.2013","article-title":"Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation","volume":"306","author":"Ren","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib70","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1053\/j.gastro.2015.04.044","article-title":"Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis","volume":"149","author":"Louvet","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib71","first-page":"1483A","article-title":"Safety AND Efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis","volume":"70","author":"Hassanein","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2021.03.006_bib72","first-page":"208","article-title":"Expression of acute-phase proteins by ELAD C3A Cells","volume":"99","author":"Landeen","year":"2015","journal-title":"Transplantation"},{"issue":"suppl 1","key":"10.1016\/j.cld.2021.03.006_bib73","first-page":"1071A","article-title":"ELAD VTL C3A cells may impact liver regeneration through secreted factors","author":"Bedard","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib74","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lt.24986","article-title":"Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial","volume":"24","author":"Thompson","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2021.03.006_bib75","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S0618-8278(19)30539-0","article-title":"A\u00a0study investigating the effect of extracorporeal cellular therapy with C3A cells on the survival of alcoholic hepatitis designed along the guidelines of the NIAAA","volume":"70","author":"Pyrsopoulos","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib76","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.30249","article-title":"Pharmacological inhibition of CCR2\/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice","volume":"69","author":"Ambade","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2021.03.006_bib77","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/hep.24599","article-title":"An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice","volume":"54","author":"Mandrekar","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib79","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of Alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cld.2021.03.006_bib80","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib81","doi-asserted-by":"crossref","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","article-title":"PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.cld.2021.03.006_bib82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0009-9120(99)00056-9","article-title":"Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in\u00a0vitro","volume":"32","author":"Hill","year":"1999","journal-title":"Clin Biochem"},{"issue":"10","key":"10.1016\/j.cld.2021.03.006_bib83","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1478-3231.2011.02604.x","article-title":"Antioxidants as therapeutic agents for liver disease","volume":"31","author":"Singal","year":"2011","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","article-title":"Milk thistle (Silybum marianum) for the therapy of liver disease","volume":"93","author":"Flora","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib85","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0168-8278(98)80285-7","article-title":"Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial","volume":"28","author":"Par\u00e9s","year":"1998","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib86","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5414\/CPP40002","article-title":"S\u00e1nchez de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study","volume":"40","author":"Lucena","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib87","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0168-8278(03)00476-8","article-title":"A\u00a0randomized placebo controlled trial of vitamin E for alcoholic hepatitis","volume":"40","author":"Mezey","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"44","key":"10.1016\/j.cld.2021.03.006_bib88","first-page":"784","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis\u2014a randomised clinical trial","volume":"2006","author":"Phillips","year":"2006"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib89","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A\u00a0randomized trial of antioxidaA randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib90","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2013.09.006","article-title":"Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits","volume":"141","author":"Rushworth","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cld.2021.03.006_bib91","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2021.03.006_bib92","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2021.03.006_bib93","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1007\/s10620-020-06142-4","article-title":"A\u00a0combination of n-acetylcysteine and prednisone has no bene t over prednisone alone in severe alcoholic hepatitis: a retrospective analysis","volume":"65","author":"Amjad","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/039463200301600304","article-title":"Metadoxine in the treatment of acute and chronic alcoholism: a review","volume":"16","author":"Addolorato","year":"2003","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib95","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1665-2681(19)30863-4","article-title":"Treatment with Metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis","volume":"13","author":"Higuera-de la Tijera","year":"2014","journal-title":"Ann Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2021.03.006_bib96","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2021.03.006_bib97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0748233710387007","article-title":"Vitamin C protective role for alcoholic liver disease in mice through regulating iron metabolism","volume":"27","author":"Guo","year":"2011","journal-title":"Toxicol Ind Health"},{"issue":"8","key":"10.1016\/j.cld.2021.03.006_bib98","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1530-0277.2009.00969.x","article-title":"Hepcidin regulation in wild-type and Hfe knockout mice in response to alcohol consumption: evidence for an alcohol-induced hypoxic response","volume":"33","author":"Heritage","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib99","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1530-0277.2006.00275.x","article-title":"Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations","volume":"31","author":"Flanagan","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13054-019-2435-4","article-title":"Adding an orange to the banana bag: vitamin C deficiency is common in alcohol use disorders","volume":"23","author":"Marik","year":"2019","journal-title":"Crit Care"},{"issue":"11","key":"10.1016\/j.cld.2021.03.006_bib101","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00134-020-06242-9","article-title":"Vitamin C and thiamine for sepsis: time to go back to fundamental principles","volume":"46","author":"Fujii","year":"2020","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/1541-4337.12171","article-title":"Health benefits of punicic acid: a review","volume":"15","author":"Aruna","year":"2016","journal-title":"Compr Rev Food Sci Food Saf"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.fct.2008.10.020","article-title":"Hepatoprotective role and antioxidant capacity of pomegranate (Punica granatum) flowers infusion against trichloroacetic acid-exposed in rats","volume":"47","author":"Celik","year":"2009","journal-title":"Food Chem Toxicol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib104","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.foodchem.2013.04.134","article-title":"Protective role of Punica granatum (pomegranate) peel and seed oil extracts on diethylnitrosamine and phenobarbital-induced hepatic injury in male rats","volume":"141","author":"Shaban","year":"2013","journal-title":"Food Chem"},{"issue":"15","key":"10.1016\/j.cld.2021.03.006_bib105","doi-asserted-by":"crossref","first-page":"13037","DOI":"10.1074\/jbc.M101632200","article-title":"Chronic ethanol exposure potentiates lipopolysaccharide liver injury despite inhibiting Jun N-terminal kinase and caspase 3 activation","volume":"277","author":"Koteish","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2021.03.006_bib106","first-page":"E59","article-title":"Chronic ethanol feeding alters miRNA expression dynamics during liver regeneration","volume":"37","author":"Dippold","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib107","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jgh.12032","article-title":"Hepatoprotectiveandanti- fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease","volume":"28","author":"Kong","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2021.03.006_bib108","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41423-018-0055-6","article-title":"Interleukin-22 from bench to bedside: a promising drug for epithelial repair","volume":"16","author":"Gao","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib109","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2010.03.004","article-title":"Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22","volume":"53","author":"Yang","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.03.006_bib110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-Escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib111","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.exphem.2004.09.005","article-title":"G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs","volume":"33","author":"Yannaki","year":"2005","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.cld.2021.03.006_bib112","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1023\/A:1025463532521","article-title":"Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy","volume":"48","author":"Theocharis","year":"2003","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2021.03.006_bib113","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hep.22317","article-title":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial","volume":"48","author":"Spahr","year":"2008","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2021.03.006_bib114","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"Singh","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2021.03.006_bib115","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:02Z","timestamp":1761069542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1089326121000301"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.03.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapies for Alcoholic Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}